Differential chemosensitization of P-glycoprotein overexpressing K562/Adr cells by withaferin A and Siamois polyphenols

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Suttana, Wipob ^a,c   Mankhetkorn, Samlee ^a   Poompimon, Wilart ^b   Palagani, Ajay ^c   Zhokhov, Sergey ^c   Gerlo, Sarah ^c   Haegeman, Guy ^c   Berghe, Wim V ^c,d  

^a CHIANG MAI UNIVERSITY   (Thailand)

^b LAMPANG RAJABHAT UNIVERSITY   (Thailand)

^c GHENT UNIVERSITY   (Belgium)

^d UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; CASPASE; CASPASE 3; DOXORUBICIN; ERIODICTYOL; GLYCOPROTEIN P; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KAEMPFEROL; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; POLYPHENOL DERIVATIVE; PROTEIN BAD; PROTEIN BCL 2; QUERCETIN; THIOL; TUBULIN; WITHAFERIN A; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; ENZYME INHIBITOR; ERGOSTEROL; FLAVONOID; INTERLEUKIN 6; PHENOL DERIVATIVE; POLYPHENOLS; SIAMOIS 1; SIAMOIS 2;

ANGIOGENESIS; ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL CYCLE; CELL LEVEL; CELL STRAIN K 562; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; GENE TARGETING; INFLAMMATION; METASTASIS; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; OXIDATION; PROTEIN CLEAVAGE; RED WINE; ANIMAL; BIOSYNTHESIS; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CASPASES; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME ACTIVATION; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERGOSTEROL; FLAVONOIDS; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; K562 CELLS; MICE; NF-KAPPA B; P-GLYCOPROTEIN; PHENOLS; QUERCETIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77953552264     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-99     Document Type: Article

References (108)

1. Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005, 5:297-309. 10.1038/nrc1588, 15803156.
2. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004, 18:2195-2224. 10.1101/gad.1228704, 15371334.
3. Schmitz ML, Mattioli I, Buss H, Kracht M. NF-kappaB: a multifaceted transcription factor regulated at several levels. Chembiochem 2004, 5:1348-1358. 10.1002/cbic.200400144, 15457532.
4. Wei H, Saladi R, Lu Y, Wang Y, Palep SR, Moore J, Phelps R, Shyong E, Lebwohl MG. Isoflavone genistein: photoprotection and clinical implications in dermatology. J Nutr 2003, 133:3811S-3819S.
5. Ahmed KM, Li JJ. ATM-NF-kappaB connection as a target for tumor radiosensitization. Curr Cancer Drug Targets 2007, 7:335-342. 10.2174/156800907780809769, 17979628.
6. Gangadharan C, Thoh M, Manna SK. Late phase activation of nuclear transcription factor kappaB by doxorubicin is mediated by interleukin-8 and induction of apoptosis via FasL. Breast Cancer Res Treat 2009,
7. Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999, 18:6938-6947. 10.1038/sj.onc.1203221, 10602468.
8. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005, 5:749-759. 10.1038/nri1703, 16175180.
9. Baeuerle PA, Baichwal VR. NF-kappa B as a frequent target for immunosuppressive and anti-inflammatory molecules. Adv Immunol 1997, 65:111-137. full_text, 9238509.
10. Duffey DC, Chen Z, Dong G, Ondrey FG, Wolf JS, Brown K, Siebenlist U, Van Waes C. Expression of a dominant-negative mutant inhibitor-kappaBalpha of nuclear factor-kappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res 1999, 59:3468-3474.
11. Barkett M, Gilmore TD. Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene 1999, 18:6910-6924. 10.1038/sj.onc.1203238, 10602466.
12. Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dorken B, Scheidereit C. Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene 1999, 18:943-953. 10.1038/sj.onc.1202351, 10023670.
13. Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 2009, 8:33-40. 10.1038/nrd2781, 2729321, 19116625.
14. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 2003, 3:768-780. 10.1038/nrc1189, 14570043.
15. Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting Inflammatory Pathways for Prevention and Therapy of Cancer: Short-Term Friend, Long-Term Foe. Clinical Cancer Research 2009, 15:425-430. 10.1158/1078-0432.CCR-08-0149, 19147746.
16. Berghe W, Dijsselbloem N, Vermeulen L, Ndlovu N, Boone E, Haegeman G. Attenuation of mitogen- and stress-activated protein kinase-1-driven nuclear factor-kappaB gene expression by soy isoflavones does not require estrogenic activity. Cancer Res 2006, 66:4852-4862. 10.1158/0008-5472.CAN-05-2957, 16651441.
17. Gong L, Li Y, Nedeljkovic-Kurepa A, Sarkar FH. Inactivation of NF-kappaB by genistein is mediated via Akt signaling pathway in breast cancer cells. Oncogene 2003, 22:4702-4709. 10.1038/sj.onc.1206583, 12879015.
18. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002, 2:48-58. 10.1038/nrc706, 11902585.
19. Biedler JL. Drug resistance: genotype versus phenotype--thirty-second G. H. A. Clowes Memorial Award Lecture. Cancer Res 1994, 54:666-678.
20. Bosch I, Croop J. P-glycoprotein multidrug resistance and cancer. Biochim Biophys Acta 1996, 1288:F37-54.
21. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989, 81:116-124. 10.1093/jnci/81.2.116, 2562856.
22. Johnstone RW. Dual mechanisms of drug resistance by p-glycoprotein inhibition of drug accumulation and caspase activation. 93rd AACR Annual Meeting 2002, 28-29. San Francisco, CA. Philadelphia: AACR.
23. Friedrich K, Wieder T, Von Haefen C, Radetzki S, Janicke R, Schulze-Osthoff K, Dorken B, Daniel PT. Overexpression of caspase-3 restores sensitivity for drug-induced apoptosis in breast cancer cell lines with acquired drug resistance. Oncogene 2001, 20:2749-2760. 10.1038/sj.onc.1204342, 11420687.
24. Ruefli AA, Tainton KM, Darcy PK, Smyth MJ, Johnstone RW. P-glycoprotein inhibits caspase-8 activation but not formation of the death inducing signal complex (disc) following Fas ligation. Cell Death Differ 2002, 9:1266-1272. 10.1038/sj.cdd.4401081, 12404126.
25. Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, Jacobs N, Gielen J, Merville MP, Bours V. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 2003, 22:90-97. 10.1038/sj.onc.1206056, 12527911.
26. Ros JE, Schuetz JD, Geuken M, Streetz K, Moshage H, Kuipers F, Manns MP, Jansen PL, Trautwein C, Muller M. Induction of Mdr1b expression by tumor necrosis factor-alpha in rat liver cells is independent of p53 but requires NF-kappaB signaling. Hepatology 2001, 33:1425-1431. 10.1053/jhep.2001.24667, 11391531.
27. Thevenod F, Friedmann JM, Katsen AD, Hauser IA. Up-regulation of multidrug resistance P-glycoprotein via nuclear factor-kappaB activation protects kidney proximal tubule cells from cadmium- and reactive oxygen species-induced apoptosis. J Biol Chem 2000, 275:1887-1896. 10.1074/jbc.275.3.1887, 10636889.
28. Kawasaki BT, Hurt EM, Mistree T, Farrar WL. Targeting cancer stem cells with phytochemicals. Mol Interv 2008, 8:174-184. 10.1124/mi.8.4.9, 18829843.
29. Obolskiy D, Pischel I, Siriwatanametanon N, Heinrich M. Garcinia mangostana L.: a phytochemical and pharmacological review. Phytother Res 2009,
30. Pinto MM, Sousa ME, Nascimento MS. Xanthone derivatives: new insights in biological activities. Curr Med Chem 2005, 12:2517-2538. 10.2174/092986705774370691, 16250875.
31. Bracke ME, Vanhoecke BW, Derycke L, Bolca S, Possemiers S, Heyerick A, Stevens CV, De Keukeleire D, Depypere HT, Verstraete W, et al. Plant polyphenolics as anti-invasive cancer agents. Anticancer Agents Med Chem 2008, 8:171-185. 10.2174/187152008783497037, 18288920.
32. Kaileh M, Berghe W, Heyerick A, Horion J, Piette J, Libert C, De Keukeleire D, Essawi T, Haegeman G. Withaferin a strongly elicits IkappaB kinase beta hyperphosphorylation concomitant with potent inhibition of its kinase activity. J Biol Chem 2007, 282:4253-4264. 10.1074/jbc.M606728200, 17150968.
33. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 2008, 269:199-225. 10.1016/j.canlet.2008.03.009, 18479807.
34. Paul AT, Gohil VM, Bhutani KK. Modulating TNF-alpha signaling with natural products. Drug Discov Today 2006, 11:725-732. 10.1016/j.drudis.2006.06.002, 16846800.
35. Harborne JB, Williams CA. Advances in flavonoid research since 1992. Phytochemistry 2000, 55:481-504. 10.1016/S0031-9422(00)00235-1, 11130659.
36. Jeyabal PV, Syed MB, Venkataraman M, Sambandham JK, Sakthisekaran D. Apigenin inhibits oxidative stress-induced macromolecular damage in N-nitrosodiethylamine (NDEA)-induced hepatocellular carcinogenesis in Wistar albino rats. Mol Carcinog 2005, 44:11-20. 10.1002/mc.20115, 15924350.
37. Formica JV, Regelson W. Review of the biology of Quercetin and related bioflavonoids. Food Chem Toxicol 1995, 33:1061-1080. 10.1016/0278-6915(95)00077-1, 8847003.
38. Csokay B, Prajda N, Weber G, Olah E. Molecular mechanisms in the antiproliferative action of quercetin. Life Sci 1997, 60:2157-2163. 10.1016/S0024-3205(97)00230-0, 9188758.
39. Terra X, Valls J, Vitrac X, Merrillon JM, Arola L, Ardevol A, Blade C, Fernandez-Larrea J, Pujadas G, Salvado J, Blay M. Grape-seed procyanidins act as antiinflammatory agents in endotoxin-stimulated RAW 264.7 macrophages by inhibiting NFkB signaling pathway. J Agric Food Chem 2007, 55:4357-4365. 10.1021/jf0633185, 17461594.
40. Choi JA, Kim JY, Lee JY, Kang CM, Kwon HJ, Yoo YD, Kim TW, Lee YS, Lee SJ. Induction of cell cycle arrest and apoptosis in human breast cancer cells by quercetin. Int J Oncol 2001, 19:837-844.
41. Patel R, Krishnan R, Ramchandani A, Maru G. Polymeric black tea polyphenols inhibit mouse skin chemical carcinogenesis by decreasing cell proliferation. Cell Prolif 2008, 41:532-553. 10.1111/j.1365-2184.2008.00528.x, 18400024.
42. Kundu JK, Hwang DM, Lee JC, Chang EJ, Shin YK, Fujii H, Sun B, Surh YJ. Inhibitory effects of oligonol on phorbol ester-induced tumor promotion and COX-2 expression in mouse skin: NF-kappaB and C/EBP as potential targets. Cancer Lett 2009, 273:86-97. 10.1016/j.canlet.2008.07.039, 18848748.
43. Dell'Eva R, Ambrosini C, Minghelli S, Noonan DM, Albini A, Ferrari N. The Akt inhibitor deguelin, is an angiopreventive agent also acting on the NF-kappaB pathway. Carcinogenesis 2007, 28:404-413. 10.1093/carcin/bgl162, 16952909.
44. Matsuda H, Yoshida K, Miyagawa K, Asao Y, Takayama S, Nakashima S, Xu F, Yoshikawa M. Rotenoids and flavonoids with anti-invasion of HT anti-proliferation of U937, and differentiation-inducing activity in HL-60 from Erycibe expansa. Bioorg Med Chem 1080, 15:1539-1546.
45. Geeraerts B, Vanhoecke B, Berghe W, Philippe J, Offner F, Deforce D. Deguelin inhibits expression of IkappaBalpha protein and induces apoptosis of B-CLL cells in vitro. Leukemia 2007, 21:1610-1618. 10.1038/sj.leu.2404788, 17568818.
46. Beltz LA, Bayer DK, Moss AL, Simet IM. Mechanisms of cancer prevention by green and black tea polyphenols. Anticancer Agents Med Chem 2006, 6:389-406. 10.2174/187152006778226468, 17017850.
47. Lin YL, Tsai SH, Lin-Shiau SY, Ho CT, Lin JK. Theaflavin-3,3'-digallate from black tea blocks the nitric oxide synthase by down-regulating the activation of NF-kappaB in macrophages. Eur J Pharmacol 1999, 367:379-388. 10.1016/S0014-2999(98)00953-4, 10079014.
48. Hamalainen M, Nieminen R, Vuorela P, Heinonen M, Moilanen E. Anti-inflammatory effects of flavonoids: genistein, kaempferol, quercetin, and daidzein inhibit STAT-1 and NF-kappaB activations, whereas flavone, isorhamnetin, naringenin, and pelargonidin inhibit only NF-kappaB activation along with their inhibitory effect on iNOS expression and NO production in activated macrophages. Mediators Inflamm 2007, 2007:45673. 10.1155/2007/45673, 2220047, 18274639.
49. Dijsselbloem N, Goriely S, Albarani V, Gerlo S, Francoz S, Marine JC, Goldman M, Haegeman G, Berghe W. A critical role for p53 in the control of NF-kappaB-dependent gene expression in TLR4-stimulated dendritic cells exposed to Genistein. J Immunol 2007, 178:5048-5057.
50. Peng Q, Wei Z, Lau BH. Pycnogenol inhibits tumor necrosis factor-alpha-induced nuclear factor kappa B activation and adhesion molecule expression in human vascular endothelial cells. Cell Mol Life Sci 2000, 57:834-841. 10.1007/s000180050045, 10892347.
51. Oak MH, Bedoui JE, Madeira SV, Chalupsky K, Schini-Kerth VB. Delphinidin and cyanidin inhibit PDGF(AB)-induced VEGF release in vascular smooth muscle cells by preventing activation of p38 MAPK and JNK. Br J Pharmacol 2006, 149:283-290. 10.1038/sj.bjp.0706843, 2014273, 16921400.
52. Corona G, Deiana M, Incani A, Vauzour D, Dessi MA, Spencer JP. Inhibition of p38/CREB phosphorylation and COX-2 expression by olive oil polyphenols underlies their anti-proliferative effects. Biochem Biophys Res Commun 2007, 362:606-611. 10.1016/j.bbrc.2007.08.049, 17727817.
53. Dechsupa S, Kothan S, Vergote J, Leger G, Martineau A, Berangeo S, Kosanlavit R, Moretti JL, Mankhetkorn S. Quercetin, Siamois 1 and Siamois 2 induce apoptosis in human breast cancer MDA-mB-435 cells xenograft in vivo. Cancer Biol Ther 2007, 6:56-61.
54. Tungjai M, Poompimon W, Loetchutinat C, Kothan S, Dechsupa N, Mankhetkorn S. Spectrophotometric Characterization of Behavior and the Predominant Species of Flavonoids in Physiological Buffer: Determination of Solubility, Lipophilicity and Anticancer Efficacy. The Open Drug Delivery Journal 2008, 2:10-19.
55. Reungpatthanaphong P, Dechsupa S, Meesungnoen J, Loetchutinat C, Mankhetkorn S. Rhodamine B as a mitochondrial probe for measurement and monitoring of mitochondrial membrane potential in drug-sensitive and -resistant cells. J Biochem Biophys Methods 2003, 57:1-16. 10.1016/S0165-022X(03)00032-0, 12834959.
56. Berghe T, Denecker G, Brouckaert G, Vadimovisch Krysko D, D'Herde K, Vandenabeele P. More than one way to die: methods to determine TNF-induced apoptosis and necrosis. Methods Mol Med 2004, 98:101-126.
57. Denecker G, Vercammen D, Steemans M, Berghe T, Brouckaert G, Van Loo G, Zhivotovsky B, Fiers W, Grooten J, Declercq W, Vandenabeele P. Death receptor-induced apoptotic and necrotic cell death: differential role of caspases and mitochondria. Cell Death Differ 2001, 8:829-840. 10.1038/sj.cdd.4400883, 11526436.
58. Berghe T, Kalai M, van Loo G, Declercq W, Vandenabeele P. Disruption of HSP90 function reverts tumor necrosis factor-induced necrosis to apoptosis. J Biol Chem 2003, 278:5622-5629. 10.1074/jbc.M208925200, 12441346.
59. Berghe W, Plaisance S, Boone E, De Bosscher K, Schmitz ML, Fiers W, Haegeman G. p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-kappaB p65 transactivation mediated by tumor necrosis factor. J Biol Chem 1998, 273:3285-3290. 10.1074/jbc.273.6.3285, 9452444.
60. Berghe W, De Bosscher K, Boone E, Plaisance S, Haegeman G. The nuclear factor-kappaB engages CBP/p300 and histone acetyltransferase activity for transcriptional activation of the interleukin-6 gene promoter. J Biol Chem 1999, 274:32091-32098. 10.1074/jbc.274.45.32091, 10542243.
61. Plaisance S, Berghe W, Boone E, Fiers W, Haegeman G. Recombination signal sequence binding protein Jkappa is constitutively bound to the NF-kappaB site of the interleukin-6 promoter and acts as a negative regulatory factor. Mol Cell Biol 1997, 17:3733-3743. 232225, 9199307.
62. Bednarski BK, Ding X, Coombe K, Baldwin AS, Kim HJ. Active roles for inhibitory kappaB kinases alpha and beta in nuclear factor-kappaB-mediated chemoresistance to doxorubicin. Mol Cancer Ther 2008, 7:1827-1835. 10.1158/1535-7163.MCT-08-0321, 2581801, 18644995.
63. Viatour P, Merville MP, Bours V, Chariot A. Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. Trends Biochem Sci 2005, 30:43-52. 10.1016/j.tibs.2004.11.009, 15653325.
64. Natoli G, Saccani S, Bosisio D, Marazzi I. Interactions of NF-kappaB with chromatin: the art of being at the right place at the right time. Nat Immunol 2005, 6:439-445. 10.1038/ni1196, 15843800.
65. Cohen P. Targeting protein kinases for the development of anti-inflammatory drugs. Curr Opin Cell Biol 2009, 21:317-324. 10.1016/j.ceb.2009.01.015, 19217767.
66. Daschner PJ, Ciolino HP, Plouzek CA, Yeh GC. Increased AP-1 activity in drug resistant human breast cancer MCF-7 cells. Breast Cancer Res Treat 1999, 53:229-240. 10.1023/A:1006138803392, 10369069.
67. Wang XJ, Sun Z, Villeneuve NF, Zhang S, Zhao F, Li Y, Chen W, Yi X, Zheng W, Wondrak GT, et al. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 2008, 29:1235-1243. 10.1093/carcin/bgn095, 18413364.
68. Chu F, Chou PM, Zheng X, Mirkin BL, Rebbaa A. Control of multidrug resistance gene mdr1 and cancer resistance to chemotherapy by the longevity gene sirt1. Cancer Res 2005, 65:10183-10187. 10.1158/0008-5472.CAN-05-2002, 16288004.
69. Gangadharan C, Thoh M, Manna SK. Inhibition of constitutive activity of nuclear transcription factor kappaB sensitizes doxorubicin-resistant cells to apoptosis. J Cell Biochem 2009, 107:203-213. 10.1002/jcb.22115, 19242952.
70. Ho WC, Dickson KM, Barker PA. Nuclear factor-kappaB induced by doxorubicin is deficient in phosphorylation and acetylation and represses nuclear factor-kappaB-dependent transcription in cancer cells. Cancer Res 2005, 65:4273-4281. 10.1158/0008-5472.CAN-04-3494, 15899819.
71. Nowak DE, Tian B, Jamaluddin M, Boldogh I, Vergara LA, Choudhary S, Brasier AR. RelA Ser276 phosphorylation is required for activation of a subset of NF-kappaB-dependent genes by recruiting cyclin-dependent kinase 9/cyclin T1 complexes. Mol Cell Biol 2008, 28:3623-3638. 10.1128/MCB.01152-07, 2423290, 18362169.
72. Huang HC, Nguyen T, Pickett CB. Regulation of the antioxidant response element by protein kinase C-mediated phosphorylation of NF-E2-related factor 2. Proc Natl Acad Sci USA 2000, 97:12475-12480. 10.1073/pnas.220418997, 18788, 11035812.
73. Berghe W, Ndlovu MN, Hoya-Arias R, Dijsselbloem N, Gerlo S, Haegeman G. Keeping up NF-kappaB appearances: epigenetic control of immunity or inflammation-triggered epigenetics. Biochem Pharmacol 2006, 72:1114-1131. 10.1016/j.bcp.2006.07.012, 16934762.
74. Dong J, Jimi E, Zhong H, Hayden MS, Ghosh S. Repression of gene expression by unphosphorylated NF-kappaB p65 through epigenetic mechanisms. Genes Dev 2008, 22:1159-1173. 10.1101/gad.1657408, 2335313, 18408078.
75. Wisman KN, Perkins AA, Jeffers MD, Hagerman AE. Accurate assessment of the bioactivities of redox-active polyphenolics in cell culture. J Agric Food Chem 2008, 56:7831-7837. 10.1021/jf8011954, 18690689.
76. Galluzzi L, Aaronson SA, Abrams J, Alnemri ES, Andrews DW, Baehrecke EH, Bazan NG, Blagosklonny MV, Blomgren K, Borner C, et al. Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ 2009,
77. Chen WY, Chang FR, Huang ZY, Chen JH, Wu YC, Wu CC. Tubocapsenolide A, a novel withanolide, inhibits proliferation and induces apoptosis in MDA-MB-231 cells by thiol oxidation of heat shock proteins. J Biol Chem 2008, 283:17184-17193. 10.1074/jbc.M709447200, 18442981.
78. Misra L, Lal P, Chaurasia ND, Sangwan RS, Sinha S, Tuli R. Selective reactivity of 2-mercaptoethanol with 5beta,6beta-epoxide in steroids from Withania somnifera. Steroids 2008, 73:245-251. 10.1016/j.steroids.2007.10.006, 18061225.
79. Devi PU. Withania somnifera Dunal (Ashwagandha): potential plant source of a promising drug for cancer chemotherapy and radiosensitization. Indian J Exp Biol 1996, 34:927-932.
80. Devi PU, Akagi K, Ostapenko V, Tanaka Y, Sugahara T. Withaferin A: a new radiosensitizer from the Indian medicinal plant Withania somnifera. Int J Radiat Biol 1996, 69:193-197. 10.1080/095530096146020, 8609455.
81. Kunsch C, Rosen CA. NF-kappa B subunit-specific regulation of the interleukin-8 promoter. Mol Cell Biol 1993, 13:6137-6146. 364673, 8413215.
82. Benayoun BA, Veitia RA. A post-translational modification code for transcription factors: sorting through a sea of signals. Trends Cell Biol 2009, 19:189-197. 10.1016/j.tcb.2009.02.003, 19328693.
83. Jacque E, Tchenio T, Piton G, Romeo PH, Baud V. RelA repression of RelB activity induces selective gene activation downstream of TNF receptors. Proc Natl Acad Sci USA 2005, 102:14635-14640. 10.1073/pnas.0507342102, 1253600, 16192349.
84. Calao M, Burny A, Quivy V, Dekoninck A, Van Lint C. A pervasive role of histone acetyltransferases and deacetylases in an NF-kappaB-signaling code. Trends Biochem Sci 2008, 33:339-349. 10.1016/j.tibs.2008.04.015, 18585916.
85. Natoli G. When sirtuins and NF-kappaB collide. Cell 2009, 136:19-21. 10.1016/j.cell.2008.12.034, 19135883.
86. Zhong H, May MJ, Jimi E, Ghosh S. The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1. Mol Cell 2002, 9:625-636. 10.1016/S1097-2765(02)00477-X, 11931769.
87. Ramirez-Carrozzi VR, Braas D, Bhatt DM, Cheng CS, Hong C, Doty KR, Black JC, Hoffmann A, Carey M, Smale ST. A unifying model for the selective regulation of inducible transcription by CpG islands and nucleosome remodeling. Cell 2009, 138:114-128. 10.1016/j.cell.2009.04.020, 19596239.
88. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003, 3:859-868. 10.1038/nrc1209, 14668816.
89. Ndlovu MN, Van Lint C, Van Wesemael K, Callebert P, Chalbos D, Haegeman G, Berghe W. Hyperactivated NF{kappa}B and AP1 transcription factors promote highly accessible chromatin and constitutive transcription across the IL6 gene promoter in metastatic breast cancer cells. Mol Cell Biol 2009, MCB.01657-08v1.
90. Smyth MJ, Krasovskis E, Sutton VR, Johnstone RW. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci USA 1998, 95:7024-7029. 10.1073/pnas.95.12.7024, 22726, 9618532.
91. Park SJ, Wu CH, Safa AR. A P-glycoprotein- and MRP1-independent doxorubicin-resistant variant of the MCF-7 breast cancer cell line with defects in caspase-6, -7, -8, -9 and -10 activation pathways. Anticancer Res 2004, 24:123-131.
92. Johnstone RW, Cretney E, Smyth MJ. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 1999, 93:1075-1085.
93. Ruefli AA, Smyth MJ, Johnstone RW. HMBA induces activation of a caspase-independent cell death pathway to overcome P-glycoprotein-mediated multidrug resistance. Blood 2000, 95:2378-2385.
94. Ascione A, Cianfriglia M, Dupuis ML, Mallano A, Sau A, Pellizzari Tregno F, Pezzola S, Caccuri AM. The glutathione S-transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol overcomes the MDR1-P-glycoprotein and MRP1-mediated multidrug resistance in acute myeloid leukemia cells. Cancer Chemother Pharmacol 2009, 64:419-424. 10.1007/s00280-009-0960-6, 19288261.
95. Turella P, Filomeni G, Dupuis ML, Ciriolo MR, Molinari A, De Maria F, Tombesi M, Cianfriglia M, Federici G, Ricci G, Caccuri AM. A strong glutathione S-transferase inhibitor overcomes the P-glycoprotein-mediated resistance in tumor cells. 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) triggers a caspase-dependent apoptosis in MDR1-expressing leukemia cells. J Biol Chem 2006, 281:23725-23732. 10.1074/jbc.M604372200, 16769721.
96. Li YC, Fung KP, Kwok TT, Lee CY, Suen YK, Kong SK. Mitochondria-targeting drug oligomycin blocked P-glycoprotein activity and triggered apoptosis in doxorubicin-resistant HepG2 cells. Chemotherapy 2004, 50:55-62. 10.1159/000077803, 15211078.
97. Pasquier E, Andre N, Braguer D. Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: implications for cancer treatment. Curr Cancer Drug Targets 2007, 7:566-581. 10.2174/156800907781662266, 17896922.
98. Fromes Y, Gounon P, Tapiero H, Fellous A. Effects of fluoro-doxorubicin (ME2303) on microtubules: influence of different classes of microtubule-associated proteins. J Protein Chem 1996, 15:561-573. 10.1007/BF01908538, 8895103.
99. Bargagna-Mohan P, Hamza A, Kim YE, Khuan Abby Ho Y, Mor-Vaknin N, Wendschlag N, Liu J, Evans RM, Markovitz DM, Zhan CG, et al. The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin. Chem Biol 2007, 14:623-634. 10.1016/j.chembiol.2007.04.010, 17584610.
100. Falsey RR, Marron MT, Gunaherath GM, Shirahatti N, Mahadevan D, Gunatilaka AA, Whitesell L. Actin microfilament aggregation induced by withaferin A is mediated by annexin II. Nat Chem Biol 2006, 2:33-38. 10.1038/nchembio755, 16408090.
101. Loo TW, Clarke DM. Determining the dimensions of the drug-binding domain of human P-glycoprotein using thiol cross-linking compounds as molecular rulers. J Biol Chem 2001, 276:36877-36880. 10.1074/jbc.C100467200, 11518701.
102. Loo TW, Clarke DM. Determining the structure and mechanism of the human multidrug resistance P-glycoprotein using cysteine-scanning mutagenesis and thiol-modification techniques. Biochim Biophys Acta 1999, 1461:315-325. 10.1016/S0005-2736(99)00165-0, 10581364.
103. Aggarwal BB. Inflammation, a silent killer in cancer is not so silent!. Curr Opin Pharmacol 2009, 9:347-350. 10.1016/j.coph.2009.06.018, 19671496.
104. Dashwood RH, Myzak MC, Ho E. Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention?. Carcinogenesis 2006, 27:344-349. 10.1093/carcin/bgi253, 2267878, 16267097.
105. Huang C, Cao P, Xie Z. Relation of promoter methylation of mdr-1 gene and histone acetylation status with multidrug resistance in MCF-7/Adr cells. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2009, 34:369-374.
106. Sharma S, Lee D, Li B, Quinlan M, Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach M, et al. A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations. Cell 2010, 141:69-80. 10.1016/j.cell.2010.02.027, 20371346.
107. Dejeux E, Ronneberg JA, Solvang H, Bukholm I, Geisler S, Aas T, Gut IG, Borresen-Dale AL, Lonning PE, Kristensen VN, Tost J. DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response. Mol Cancer 9:68. 10.1186/1476-4598-9-68, 2861056, 20338046.
108. Mishra MV, Bisht KS, Sun L, Muldoon-Jacobs K, Awwad R, Kaushal A, Nguyen P, Huang L, Pennington JD, Markovina S, et al. DNMT1 as a molecular target in a multimodality-resistant phenotype in tumor cells. Mol Cancer Res 2008, 6:243-249. 10.1158/1541-7786.MCR-07-0373, 18314485.